66 results about "Liver fat" patented technology

The invention discloses an FAM20B protein and application of an FAM20B protein inhibitor in prevention or treatment of glucolipid metabolism related diseases. Specifically, the invention discloses an application of an FAM20B protein and / or an FAM20B gene in regulation and control of liver glycolipid metabolism. The invention also discloses application of the FAM20B inhibitor in improving, preventing or treating liver glycolipid metabolism disorder or glycolipid metabolism related diseases (such as diabetes, metabolism related fatty liver disease MAFLD, obesity and the like). Experiments show that the FAM20B inhibitor can reduce the liver gluconeogenesis level, relieve impairment of glucose tolerance, relieve hyperglycemia of diabetic patients, reduce the fat content of the whole body and the liver, relieve liver lipid deposition, promote energy consumption, reduce food intake, promote fat burning and reduce liver fat accumulation; the compound can be used for preparing medicines for preventing and treating glucose and lipid metabolism disorder or glucose and lipid metabolism related diseases, and has a wide application prospect in the fields of prevention and treatment of metabolism related diseases.

The application discloses a method for simulating a magnetic resonance signal of fatty liver tissue, which comprises the following five steps: obtaining a proton density fat fraction (PDFF) and an effective transverse relaxation rate parameter of the fatty liver tissue; and the method has the beneficial effects that: a three-dimensional simulation model of the fatty liver tissue with different fat fractions is simulated, the PDFF and the predicted value corresponding to the fat fraction are obtained, and thus a correction relationship between the fat fraction and the parameter is established; meanwhile, by adjusting the parameters (magnetic field strength, etc.) in the three-dimensional simulation model of the fatty liver tissue, the influence of fat on the parameter can be corrected in different scenes; and the method can improve the quantification accuracy of liver iron and liver fat through the correlation between the fat fraction and the parameter.

The invention discloses a traditional Chinese medicine composition and application thereof in medicine for improving non-alcoholic fatty liver, and the traditional Chinese medicine composition comprises pulvis fellis suis, pericarpium citri reticulatae, hawthorn and clostridium butyricum. On one hand, potential targets and pathways of drug diseases are determined in network pharmacological analysis, and on the other hand, in an in-vivo experiment, the drug provided by the invention improves obesity and impaired glucose tolerance caused by HFD, reduces the blood fat level, alleviates inflammation, protects the liver, alleviates liver fat vacuole deposition and fatty degeneration, and has a good application prospect. It is proved that the bile acid-hawthorn and pericarpium citri reticulatae-clostridium butyricum combination has prevention and treatment and protection effects on the HFD-induced non-alcoholic fatty liver disease.

The application relates to the technical field of medical treatment and discloses a liver chronic disease screening method, a device and a storage medium.The method comprises the following steps: a liver detection system collects liver stiffness data and liver fat attenuation parameters of a target object; a mobile terminal system receives the liver stiffness data and the liver fat attenuation parameters, combines the liver stiffness data and the liver fat attenuation parameters with basic information of a preset target object, generates acquisition characteristic data, carries out label marking matrix processing on pretreatment integrated data of the cloud service system, generates a label marking matrix, carries out fitting residual processing on the label marking matrix, obtains extended decision tree data, carries out discrete sampling processing on the extended decision tree data, obtains a sparse vector, carries out classification calculation processing on the sparse vector, obtains a classification result, and generates a disease screening report based on the classification result.In the embodiment of the application, through system architecture and cloud service system data processing, the early warning timeliness and accuracy of liver chronic disease screening are improved.

The present invention relates to the technical field of microorganisms, in particular to a Lactobacillus acidophilus GOLDGUT-LA100 having functions of lipid lowering, blood glucose lowering and weight loss and application thereof. The Lactobacillus acidophilus GOLDGUT-LA100 provided by the present invention is preserved in China General Microbiological Culture Collection Center, with the preservation number of CGMCC No. 28398. The strain has strong acid resistance, can adapt to the digestive tract environment, and has high bile salt hydrolase activity. At the same time, in animal experiments, the strain significantly reduces blood glucose and serum cholesterol levels, reduces liver fat deposition, reduces adipose tissue inflammation, effectively reduces the weight, and has broad application prospects in the development of products for improving obesity, lowering lipid and lowering blood glucose.

1. The name of the design product: liver fat measuring instrument. 2. The use of the design product: for detecting and evaluating liver fat. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

The invention discloses application of an Fn1-PPARbeta / delta signal channel related to a cardiac liver disease. The cardiac liver disease model is constructed according to the conditions that the liver development of young individuals is delayed due to heart injury and both adult and young individuals have serious fatty livers. In the model, the Fn1 protein level in the heart and blood is obviously increased compared with the normal level. Based on a zebra fish heart ablation means, after heart ablation injury, the heart specific knock-down Fn1 can lead to reduction of the Fn1 protein level in blood and alleviation of liver development retardation and fat deposition. Through the screening of transcriptomics, the PPARbeta / delta protein in the liver is found to be a potential downstream effect factor of Fn1. The liver specific overexpression PPARbeta / delta protein can significantly relieve abnormal phenotypes such as liver fat deposition caused by heart injury, and after the liver specific knock-down PPARbeta / delta protein, the protection effect of knock-down Fn1 on the liver disappears under the condition of heart injury. Therefore, the Fn1 protein and the PPARbeta / delta protein can be used as targets for preventing and treating the cardiac liver injury, and are used for preparing medicines for improving the cardiac liver injury, so that a new way is provided for treating the cardiac liver disease.

The invention relates to the field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition and a preparation method and application thereof. The traditional Chinese medicine composition provided by the invention comprises astragalus membranaceus, cinnamon, semen cassiae, lotus leaves, poria cocos, lophatherum gracile, malt, hawthorn, rose, pogostemon cablin, sophora flower, semen torreya and emblic leafflower fruit. The formula takes the effects of tonifying spleen and promoting diuresis, soothing liver and regulating qi, and removing food retention and dissolving turbidity as the core, and has multiple effects of promoting urination and relieving stasis. The traditional Chinese medicine composition provided by the invention can regulate and control abnormal signal pathways of fatty liver and atherosclerosis; the compound has no obvious inhibition effect on a hepatic cell line HepG2 and has an inhibition effect on a hepatic stellate cell line LX2; the obvious lipid-lowering effect is achieved on a HepG2 high-lipid model; liver fat accumulation and liver injury in a TAA-induced zebrafish fatty liver model can be remarkably improved.

The invention provides a composition for relieving fatty liver and application thereof, and belongs to the technical field of medicines. The composition disclosed by the invention is prepared from the following components: dihydroberberine, neoruscogenin, hispidulin and trans-trimethoxy resveratrol, wherein the final concentration of the dihydroberberine, the final concentration of the neoruscogenin, the final concentration of the hispidulin and the final concentration of the trans-trimethoxy resveratrol are all 5 to 15 [mu] M. The composition disclosed by the invention can be used for effectively relieving liver fat accumulation, liver function damage and liver oxidative stress injury, and has a good application prospect as a new product for preventing and controlling the fatty liver.

The present application belongs to the field of nutritional composition and biological medicine technology, and particularly relates to a composition for protecting and preserving liver, a preparation method, application and product thereof. The composition of the present application is composed of extract of Silybum marianum, glucoraphanin and extract of Cynara scolymus. The composition of the present application can intervene the pathological process of liver injury from multiple dimensions such as antioxidation, anti-inflammation, regulation of lipid metabolism and repair of hepatocytes through synergistic effect of the three components, significantly reduces the levels of glutamic-pyruvic transaminase and glutamic-oxalacetic transaminase, reduces the accumulation of liver fat, improves the antioxidant capacity of the body, effectively prevents or improves alcoholic, chemical, non-alcoholic fatty and autoimmune liver injury, delays the progression of liver fibrosis, and comprehensively maintains the structural integrity and functional stability of the liver.

The invention discloses a fermented sausage source active peptide as well as a preparation method and application thereof in preparation of medicines for preventing and treating alcoholic liver injury, and belongs to the technical field of biological medicines. The amino acid sequence of the fermented sausage source active peptide comprises one or more of WLKLRPILK and RGPPRPRPAPA. The method disclosed by the invention has the beneficial effects that the bioactive peptide can be efficiently extracted from the minced pork within a relatively short time. The active peptide has a remarkable relieving advantage on alcoholic liver injury, and can inhibit liver fat synthesis increase caused by alcohol intake and promote catabolism of fatty acid through an AMPK pathway. And a peptide fragment with an AMPK activation effect is rapidly screened through computer screening and molecular docking. The method has high reference value for low-cost preparation of the fermented meat-derived active peptide and prevention of alcoholic liver injury, and is suitable for popularization and application.

The present application discloses the use of FGF21 / GLP-1 fusion proteins in the preparation of a medicament for preventing and / or treating at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia. The FGF21 / GLP-1 fusion proteins of the present application are effective in treating at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia, and in particular, can reduce at least one of HbA1c, blood glucose, body weight, liver fat content, ALT, AST, glutamyl transpeptidase, triglyceride, total cholesterol, low-density lipoprotein cholesterol, or increase at least one of adiponectin, insulin sensitivity, and beta-cell function in the subject.

The present invention provides a compound for use in reducing liver fat in a subject, wherein the compound is selected from:(i) (R)-3-hydroxybutyrate;(ii) an ester of (R)-3-hydroxybutyrate; and(iii) an oligomer obtainable by polymerising (R)-3-hydroxybutyrate moieties;or a pharmaceutically acceptable salt or solvate thereof. The compound is particularly useful in subjects suffering from a fatty liver. The compound can be used to treat non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH) or non-alcoholic fatty liver (NAFL).

The invention relates to the field of medical preparations, in particular to application of ingenol in preparation of a medicine for treating liver injury of postmenopausal women. The ingenol intervenes in OVX to induce a postmenopausal obese mouse, and the ingenol is proved to be capable of remarkably reducing the weight and fat content of the mouse, reducing serum TC, TG and LDL-c level rise, improving hepatocyte swelling and reducing the number of liver fat droplets, and also capable of remarkably reducing serum AST and ALT level rise caused by OVX and relieving liver injury induced by OVX. Therefore, the ingenol can be used for effectively treating the liver injury of the postmenopausal women, and can be used for preparing a medicine for treating the liver injury of the postmenopausal women and a medicine for reducing the level of a liver injury marker in serum. The method can provide a new direction and strategy for future development and application of ingenol.

Provided are a novel bile acid derivative for treating fatty liver disease, a pharmaceutical composition thereof, and a use in the preparation of a medicine for treating and improving diseases and symptoms mediated or caused by FXR or TGR5. The bile acid derivative of the present invention inhibits or delays the metabolism of bile acid by bacterial BSH / 7α dehydroxylase in the intestine and greatly prolongs the effective survival time of bile acid in the intestine. The bile acid derivative and the pharmaceutical composition thereof can significantly stimulate bile acid membrane receptor TGR5, promote the secretion of glucagon-like peptide 1 from enteroendocrine cells, reduce liver fat accumulation, significantly improve liver function and increase glucose tolerance, thereby having an excellent effect on the treatment of fatty liver disease.

A patent obtained in the earlier stage is that the line peptide COX52-69 is cyclized to realize an oral administration route. The invention finds that the cyclic peptide has the effect of reducing body weight. The invention is named as application of the polypeptide COX52-69 in reducing liver fat accumulation and fat cell volume. In the invention, a diet-induced obesity (DIO) model is established by feeding C57BL / 6J mice with high-fat feed (45% of fat for energy supply) for 14 weeks. After a DIO mouse is obtained, a 17-week administration experiment is carried out by using a PBS buffer solution and a Rybelsus solution as a contrast, and observation finds that the COX52-69 cyclic peptide can reduce liver fat accumulation and reduce the fat cell volume of fat tissue while reducing the weight of the DIO mouse. Therefore, the COX52-69 cyclic peptide has practical application in improving the volume of the fatty liver and the fat cells.

The invention relates to application of a fingered citron extract in preparation of a medicine for treating metabolic syndrome, and belongs to the technical field of biological medicines. According to the fingered citron extract disclosed by the invention, the diversity of flora can be improved by regulating intestinal flora, and the relative abundance of beneficial bacteria Akkermansia is specifically increased, so that the metabolic syndrome induced by high fat diet is relieved. An embodiment verifies that the scheme of the invention not only can significantly inhibit weight gain of obese mice induced by high fat diet, improve glucose metabolism disorder (including reduction of fasting blood-glucose and improvement of oral glucose tolerance), relieve liver fat accumulation and pathological damage, reduce visceral fat accumulation and improve adipocyte hypertrophy, but also can significantly inhibit the weight gain of the obese mice induced by high fat diet and improve the glucose metabolism disorder (including reduction of fasting blood-glucose and improvement of oral glucose tolerance). And obesity-related metabolic hormone disorder can be effectively reversed, for example, the serum insulin level is improved, and the leptin level is reduced.

The present invention relates to a composition for preventing, alleviating, or treating fatty liver, comprising gintonin derived from red ginseng meal as an active ingredient. The present invention uses gintonin isolated from by-products of red ginseng, which is widely used as a health functional food, and thus has almost no side effects, is safe, and has the advantage of lowering unit cost to enable long-term administration. In addition, anti-obesity, metabolic rate increase, and liver fat accumulation inhibitory effects thereof were identified through specific experiments, and thus the present invention is expected to be effectively used as a pharmaceutical, food or the like for preventing, alleviating, or treating fatty liver disease.

The invention discloses functional feed for protecting liver and intestines of mandarin fish and a preparation method of the functional feed, and belongs to the technical field of feed. The functional feed for protecting the liver and the intestine of the mandarin fish comprises the following components: an intestine and liver protecting compound, an enteric coating material, an adsorbent, an anti-sticking agent, a protein source, a fat source, carbohydrate, compound vitamins and compound minerals. The preparation method comprises the following steps: firstly, preparing a coating solution, putting an intestine and liver protecting compound into a fluidized bed, spraying the coating solution at the bottom, curing, adding an adsorbent, and mixing to obtain a coated compound; then mixing a protein source, a fat source and carbohydrate to obtain a basic nutrient; and finally, mixing the coated compound, the basic nutrient mixture, the compound vitamins and the compound minerals, extruding and granulating, spraying an anti-sticking agent, and drying to obtain the feed. The functional feed for protecting liver and intestine of mandarin fish provided by the invention can inhibit fatty acid synthase in liver, reduce liver lipid deposition of mandarin fish, restore the liver-body ratio, improve the feed conversion rate and enhance the growth performance of mandarin fish.

The application discloses a kind of multi-frame image fatty liver content detection method and system based on motion inhibition, belong to medical image processing technical field, which comprises: selecting region of interest in patient liver region and setting processing time;Under B mode ultrasonic scanning, liver image is acquired in real time;Liver parenchyma probability weight distribution map is generated to each frame image;Interframe motion estimation is carried out, and the image frame with motion amplitude in preset threshold is screened out;Nonlinear parameter scanning is carried out, and corresponding nonlinear parameter matrix is obtained;Each element in each nonlinear parameter matrix is converted into liver fat content value, and corresponding liver fat content score matrix is obtained;Kalman filtering algorithm is applied to multiple liver fat content score matrixes to carry out fusion filtering processing, and finally liver fat content quantitative value is obtained.The method can realize non-invasive, accurate and quantitative liver fat content detection;It can be integrated into ultrasonic diagnostic equipment and is suitable for hospitals, medical centers and other scenes.

A method for predicting one or more adipose depots for a patient includes receiving one or more Dual-energy X-ray Absorptiometry (DEXA) scans comprising at least a portion of a torso of the patient; p

The invention discloses a nuclear magnetic image processing method and device for liver fat content determination. The method comprises the steps that a to-be-processed original image and text information of a target area are acquired; inputting the original image and the text information into a pre-trained image processing model to obtain a segmentation result of a target area output by the image processing model; copying the target area to a pre-stored fat phase diagram to obtain a corresponding area of the target area in the fat phase diagram; removing the volume effect of the corresponding region by using a corrosion algorithm to obtain a final target region; and calculating the gray value of the final target area to obtain the fat content value of the target area. In auxiliary analysis of fatty liver quantitative evaluation, the method and the device can improve image processing efficiency, improve image processing accuracy and reduce labor cost.

1. Name of this product design: Liver fat detection probe. 2. Purpose of this design: A liver fat detection probe for liver fat detection. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The application provides an application of ursodeoxycholic acid in preparation of an environmental stress induction caused fish disease related product, and the application comprises one of the following: an application in preparation of a drug for preventing an environmental stress induction related fish disease; an application in preparation of a drug for reducing, treating or assisting in treating an environmental stress induction related fish disease; and an application in preparation of a feed, a feed raw material, a feed additive or a feed composition for improving an environmental stress induction related fish disease. The application proves by experiments that adding a certain dose of ursodeoxycholic acid in the feed can significantly relieve pathological damage of liver of crucian caused by environmental stress factors such as ammonia nitrogen and nitrite, including reducing hepatocyte vacuolization, karyopyknosis and inflammatory cell infiltration, and reducing pathological deposition of liver fat.

An ultrasound imaging system may acquire an image of a liver. The liver may be segmented from the image. Parameters, such as image homogeneity map, intensity probability chart, and / or speckle size diagram, may be extracted from the liver portion of the image. The parameters may be used to determine whether fatty liver deposits are diffuse or inhomogeneous. In some examples, inhomogeneous regions may be excluded from the calculation of liver fat quantification measurements. In some examples, the inhomogeneous regions may be displayed so that a user may select a region of interest that excludes the inhomogeneous regions to calculate the liver fat quantification measurements.

The invention provides a tablet for assisting in protecting liver injury and improving liver fat metabolism and a preparation method of the tablet, and belongs to the technical field of biological pharmacy. The tablet for assisting in protecting liver injury and improving liver fat metabolism comprises a yeast extract, dihydroquercetin, curcumin composite powder, a filling agent and a lubricant, and the curcumin composite powder is prepared by the following steps: dissolving curcumin in a 95% ethanol solution, adding croscarmellose sodium, uniformly mixing, and performing freeze drying to obtain the curcumin composite powder. The preparation method comprises the following steps: adding water under a high-speed stirring condition, carrying out reduced pressure distillation, carrying out vacuum drying to obtain a curcumin-croscarmellose sodium compound, adding silicon dioxide and crushed ice, mixing, and carrying out low-temperature ball milling to obtain the curcumin-croscarmellose sodium compound. According to the invention, the problems of tabletting and forming of the curcumin and the yeast extract are solved, the prepared tablet is high in hardness, low in friability and smooth in surface, and the water solubility and bioavailability of the curcumin are improved.

The invention relates to the field of environmental exposure omics and metabolic diseases, in particular to application of chlorpyrifos and paraquat in preparation of an abdominal obesity diagnosis product. The abdominal fat area, the A / S ratio, the liver fat content and other indexes measured through quantitative computed tomography (qCT) are combined, accurate recognition of abdominal obesity is achieved, the subjects with the normal body mass index (BMI) and visceral fat exceeding the standard can be effectively recognized, and the method has the advantages of being high in sensitivity, high in specificity and good in diagnosis foresight and has good application prospects. A new scheme is provided for early risk assessment and clinical screening of abdominal obesity, the significant correlation between the high exposure level of chlorpyrifos and paraquat and abdominal obesity supports the hypothesis that environmental endocrine disruptors promote obesity through metabolism interference, the urine concentration of chlorpyrifos and paraquat can be used as a novel biomarker, and the application prospect is broad. And a potential tool is provided for early screening of abdominal obesity.

The application discloses application of Rezafetin in preparation of a medicine for treating non-alcoholic fatty liver disease. The application first discovers that the compound has good treatment effect in a non-alcoholic fatty liver disease (NASH) model. Through in-vivo experiments, it is confirmed that in a NASH model mouse, the Rezafetin can significantly reduce pathological characteristics such as liver weight, liver fat level and liver index. Meanwhile, the Rezafetin treatment can significantly reduce the level of serum transaminase (ALT / AST), indicating that the Rezafetin effectively improves liver damage and liver function. The application provides a brand-new and effective drug treatment strategy for clinically treating NASH, and has significant clinical application value and market prospect.

The present application relates to the technical field of medical image recognition, in particular to a fat content analysis method and system based on liver pathological section images, comprising the following steps: extracting liver fat vacuole barycenter sequence, identifying arrangement mutation nodes, eliminating abnormal vacuoles, analyzing boundary structure, extracting closed boundary, and generating fat content analysis results. In the present application, by selecting the structure edge adjacent pixel group in the fat vacuole area and constructing the barycenter sequence, the deep representation of the fat vacuole arrangement feature is realized, and a stable reference is provided for subsequent structure recognition; based on the evolution trend of the adjacent barycenter vector included angle in the barycenter sequence, the abnormal change nodes are identified, the arrangement direction mutation points are effectively located, the impurity interference is screened out, and the misjudgment of fat evaluation caused by irregular accumulation is avoided; with the help of barycenter drift curve and compactness variation coefficient calculation, the morphological fluctuation area is identified and abnormal vacuoles are eliminated, and the consistency and stability of structure extraction are enhanced.

The present invention provides diagnostic and / or prognostic markers indicative of liver fat, fatty liver diseases (e.g. non-alcoholic fatty liver disease (NAFLD) and / or hepatocellular cancer deriving